🏛️ Verified NIH Record • Updated 2025-04-29
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency (NCT06046820)
The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Inozyme Pharma
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital of Colorado — Aurora, Colorado
Age range: 1 Year to 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Children's Hospital of Colorado — Aurora, Colorado
- Ann & Robert H. Lurie Children's Hospital — Chicago, Illinois
- Boston Children's Hospital — Boston, Massachusetts
- Nationwide Children's Hospital — Columbus, Ohio
- The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Cook Children's Medical Center — Fort Worth, Texas
- Queensland Children's Hospital — South Brisbane,
- Centre Hospitalier Universitaire (CHU) Sainte-Justine — Montreal,
- Hôpital Bicêtre, Service d'endocrinologie et diabète de l'enfant (Childhood Endocrinology and Diabetes Department) — Le Kremlin-Bicêtre,
- King Faisal Specialist Hospital and Research Centre — Riyadh,
- Hospital San Joan de Deu — Barcelona,
- Umraniye Training and Research Hospital — Istanbul,
- Cukurova Universitesi Tip Fakultesi — Sarıçam,
- Al Jalila Children's Specialty Hospital — Dubai,
- Royal Manchester Children's Hospital — Manchester,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency
Explore by condition: All Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.